Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Moderna, Inc. — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.4 (market cap $162.00B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 2.1× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Moderna, Inc. for 59 Days on average.
| IEMG | MRNA | |
|---|---|---|
Market Cap | $162.00B | $78.65B |
Volume | 13,446,151 | 37,373,437 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $203.46 |
52-Week Low | $64.22 | $22.36 |
Typical Hold Time | 57 Days | 59 Days |
Enterprise Value | — | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG is trading at $80.5, down 1.88% over the past 24 hours amid a bearish technical signal. The ETF's technical indicators show selling pressure with moving averages signaling bearish momentum, though oscillators remain neutral. Recent news highlights IEMG's strong performance against emerging market peers, with the fund delivering 35% returns over the past year according to Fool - Investing News on 2026-07-06, though it faces higher volatility than broader international alternatives.
The outlook for IEMG remains mixed with technical weakness offset by strong recent performance in emerging markets. Key risks include concentration in technology sectors (39% weighting) and higher volatility compared to developed market ETFs. Analyst comparisons favor IEMG for emerging market exposure but note cost disadvantages versus competitors like SCHE with its 0.03% expense ratio versus IEMG's 0.09%.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
